

		Team Control Number		
For office use only		36428		For office use only
T1	_____			F1
T2	_____			F2
T3	_____			F3
T4	_____			F4
		Problem Chosen		
		A		

2015 Mathematical Contest in Modeling (MCM) Summary Sheet
 (Attach a copy of this page to each copy of your solution paper.)

Abstract

The Ebola virus disease(EVD) is a lethal disease for humans and other primates caused by the deadly Ebola virus. According to the WHO long-term trace, the fatality rate of Ebola is up to 85%, just second to the well-known lupomania. Fortunately, in this competition, we have been set in a background with the invention of new medication which could stop Ebola dispersal and cure patients with early symptoms.

Our mission is to establish a model to numerically describe both the dispersal process of the lethal infection, and human being's process to manufacture, deliver and treat Ebola with this medicine. In order to implement such subtle and exciting procedures to fight against the Azrael, we deliberately divide the procedures into two major steps: modelling the Ebola virus' basic spread progress in ideal cases at a particular region; modelling human being's hygiene actions and medicine delivery process, incorporating our fighting model into the virus' instinct properties and evaluating the results.

In the first model, we modify the classical **Susceptible, Infective, Removal(SIR)** model in epidemic dynamic fields into our **SID(Death)** model. The **SID** model is meant to help us observing the disastrous infection process of Ebola in none human interference conditions. With the default attributes settings, we successfully generate a real-time simulation result of the spread and attacking process in Western Africa districts.

However, in the primary **SID** model, all the parameters are set in a way lacking of consideration in real life. This makes the simulation result too ideal to be feasible in practice. This is just the motivation for us to establish the second model. In the second model, we expand the **SID** model to a brand-new one: **Susceptible, Primary, Advanced, Recovery, Death(SPARD)**. All parameters in **SPARD** are dynamic changing, which means a much more precise and subtle system. In addition, we develop a **Early Warning System(EWS)** to help doctors monitoring and determining the demand of medicine in real-time. We prove our **SPARD** model has considerable number of advantages to help fighting against EVD by providing vivid raw data, figures and simulation results in the experiment part. According to the simulation result, the EVD outbreak can be suspended in approximately 200days.

Fight against the Azrael: A optimized plan to eradicate Ebola

Team #36428

March 4, 2015

Abstract

The Ebola virus disease(EVD) is a lethal disease for humans and other primates caused by the deadly Ebola virus. According to the WHO long-term trace, the fatality rate of Ebola is up to 85%, just second to the well-known lupomania. Fortunately, in this competition, we have been set in a background with the invention of new medication which could stop Ebola dispersal and cure patients with early symptoms.

Our mission is to establish a model to numerically describe both the dispersal process of the lethal infection, and human being's process to manufacture, deliver and treat Ebola with this medicine. In order to implement such subtle and exciting procedures to fight against the Azrael, we deliberately divide the procedures into two major steps: modelling the Ebola virus' basic spread progress in ideal cases at a particular region; modelling human being's hygiene actions and medicine delivery process, incorporating our fighting model into the virus' instinct properties and evaluating the results.

In the first model, we modify the classical Susceptible, Infective, Removal(**SIR**) model in epidemic dynamic fields into our **SID**(Death) model. The **SID** model is meant to help us observing the disastrous infection process of Ebola in none human interference conditions. With the default attributes settings, we successfully generate a real-time simulation result of the spread and attacking process in Western Africa districts.

However, in the primary **SID** model, all the parameters are set in a way lacking of consideration in real life. This makes the simulation result too ideal to be feasible in practice. This is just the motivation for us to establish the second model. In the second model, we expand the **SID** model to a brand-new one: Susceptible, Primary, Advanced, Recovery, Death(**SPARD**). All parameters in **SPARD** are dynamic changing, which means a much more precise and subtle system. In addition, we develop a Early Warning System(EWS) to help doctors monitoring and determining the demand of medicine in real-time. We prove our **SPARD** model has considerable number of advantages to help fighting against EVD by providing vivid raw data, figures and simulation results in the experiment part. According to the simulation result, the EVD outbreak can be suspended in approximately 200days.

Keywords: EVD, SIR, SPARD, Early Warning, Graph Optimization, real-time simulation

Contents

1	Introduction	4
2	Sub-model 1: SID-The dispersal of the Azrael in ideal cases	4
2.1	Symbols and Notations	4
2.2	Analysis and Assumptions	5
2.3	Model Description	6
2.4	Experiment Result	7
2.5	Strengths and Weaknesses	9
3	Sub-model 2: SPARD-Improved EVD dynamic dispersal model	9
3.1	Symbols and Notations	9
3.2	Analysis and Assumptions	10
3.3	Model Description	11
3.3.1	General Model	11
3.3.2	Objective Condition Model	11
3.3.3	S-P Transition Model	13
3.3.4	A-D Transition Model	13
3.3.5	P-A Transition Model	14
3.3.6	P-R Transition Model	14
3.3.7	S-R Transition Model	14
3.3.8	Medication Demand and EWS	15
3.3.9	Transport Optimization	17
3.4	Experiment Result	18
3.5	Strengths and Weaknesses	20
4	Conclusion	23
5	The non-technical letter	23
	Appendices	27
	Appendix A Raw data in SPARD model	27
A.1	Western African city data used in our simulation	27
A.2	Simulation raw data of S, P, A(sampled with 5 days interval	27

1 Introduction

According to the statistical data collected by World Health Organization(WHO)[1], the current Ebola virus disease (EVD) outbreak ravaging three nations in West Africa has affected more than 14,000 persons and killed over 5,000. It is the longest and most widely spread Ebola epidemic ever seen.

In this problem, a new medication has just been released by the world medical association. We are required to undertake the duty of fight against the Azrael with the aid of this medicine: establishing a realistic sensible and useful model that consider various factors including spread speed, medicine manufacturing speed, delivery system, etc. In order to accomplish such a huge task, we establish two sub-models:

- **Sub-model 1:** A model which describes the virus dispersal process in ideal settings.
- **Sub-model 2:** A model contains the deep relationship between the medication manufacturing, delivery, applying flow and the infection, immune process of EVD.

In sub-model 1, we implement a real-time simulation system by Matlab to simulate the dispersal process of Ebola in ideal cases. We modify the **SIR** model into our **SID** one and exhibit you with touchable and vivid figures.

In sub-model 2, by surveying a large amount of real data, scientific paper available, we propose an all new model: **SPARD**, which takes not only: spread speed, harmfulness, delivery system, but also: manufacturing speed, dispersal path as essential factors into consideration. In addition, all these factors in **SPARD** model are dynamic changing and they provide us with a warning system which can aid us finding the trend of EVD dispersal as soon as possible.

The structure of the paper is organized by two sub-models, respectively. In each sub-model, we give our own analysis, assumptions, models descriptions, experiment results and strengths/weaknesses analysis. The final conclusion is given in section 4. In section 5, we provide our non-technical letter intended for world citizens. The appendix offers the raw data of our **SPARD** model.

2 Sub-model 1: SID-The dispersal of the Azrael in ideal cases

2.1 Symbols and Notations

Table 1: Major Symbol and Notation list for sub-model 1

Symbols and Notations	
Symbol/Notation	Definition
τ	The transmission probability from susceptible to infective
μ	The transmission probability from infective to death
$S(t)$	The number of susceptible people at time t
$I(t)$	The number of infected people at time t
$D(t)$	The number of dead people at time t
N	The total population in one district(default: 1 unit)
t_{max}	Maximum simulation days
k	Average days to death after infected

2.2 Analysis and Assumptions

In this section, our goal is to construct a model which can provide us with a direct and visible Ebola spread process in those highlighted areas, specifically without any sanitation interference. The goal for constructing such a primary model is to set up a fundamental pipeline for further models, which introduced in the third sections. According to the official document, Guidance for Immunization Programmes in the African Region[2], released in Oct. 2014, at the present EVD outbreak, the top three countries in EVD crisis, which means they own the most detected cases and fatality rates, are *Guinea, Liberia and Sierra Leone*. Besides, *Cote d'Ivoire, Guinea Bissau, Mali* and another eleven countries are in high infection risk. Just as we shown in **figure 1**, those countries are mostly in Western African regions.

In addition, according to another technical report[3] the common approach of EVD's spread are: human direct contacts, body fluid exchange, inappropriate bury, etc. One of the issues worthy noting is that no evidence yet attests that there exists human-stock dispersal path or ocean movement dispersal path. In other words, the spread of EVD major relies on high population density and commences from those inner parts of the continent. These facts imply that our EVD dispersal spread point in the simulation should be set in metropolitans. Besides, in order




Figure 1: The present status of Ebola in Western African areas, according to WHO website

to direct observe the disastrous effect of Ebola and utilize the classical **SIR** model, we survey the Ebola's infection probability for a given patient from [4]. For simplification purpose, we utilize the "max-pooling" strategy to select our infectious probability τ . And because we assume there does not exist any health or medication care system, we set the death rate μ as 100% for those infected inhabitants. Finally, due to the fact that the incubation period for an EVD patient ranges from 2-21 days[5], we suppose that the life-span only depends on the average incubation period.

On the basis of the analysis above, we summarize our assumptions as below:

- **Assumption 1-1:** The starting points of the dispersal should be those medium or big size cities rather than other points on the map.
- **Assumption 1-2:** There is not any human medical-care action to impede or stop Ebola's

spread. As long as someone is infected by EVD, he or she is bounded to death, i.e., $\mu = 100\%$.

- **Assumption 1-3:** The dispersal approach only includes continent-adjacent dispersal way.
- **Assumption 1-4:** The lifespan for an infected people k is a constant depending on the incubation period. In this case, $k = 13$.

2.3 Model Description

In this subsection, we briefly introduce the classical **Susceptible, Infective, Removal(SIR)** model[6] in epidemic dynamic fields and our modification work on it. Besides, we will introduce the input parameters, output parameters and the basic flow of our simulation system.

First and foremost, according to the **SIR** model, as long as a particular region is affected by the Ebola, the whole population can be divided into three separate parts: **Susceptible**(People who are still in healthy status); **Infective**(People who have already caught the EVD); **Removal (SIR)**(People who have already recovered and is immune to EVD). Nonetheless, on the basis on **Assumption 1-2**, there should not be any recovered inhabitants. When we recall the fact that no matter recovered or death people are immune to the disease and are not able to further affect susceptible individuals. We can simply consider that "Removal" is equivalent to "Death"; therefore, we can modify **SIR** into **SID(death)** by setting D's immune index at 0(because they have already died). In addition, we assume that D class people are immediately buried appropriately after death.

Furthermore, the core part of the **SID** model can be described with two transmission probabilities: susceptible-infective: τ and infective-death: μ . Based on our early premises, μ has already selected at 100%. As to calculating susceptible-infective transmission probability τ , we utilize the apex value in [7], just as shown in **figure 2**. Therefore, we set τ at 0.4.




Figure 2: The probability of infecting susceptible people of an EVD patient, with respect to time

According to **Assumption 1-4**, the lifespan for infected people $k = 13days$. Finally, The

behaviour of our **SID** model can be described by a group of differential equations as below:

$$\left\{ \begin{array}{l} S(t) + I(t) + D(t) = N \\ \frac{dS}{dt} = -\tau SI \\ \frac{dI}{dt} = \tau SI - I\mu \\ \frac{dD}{dt} = I\mu \\ S(0) = N, I(0) = 0, D(0) = 0 \end{array} \right. \quad (1)$$

Note that N is the total population of a specific district; at the initial state, all the inhabitants in one district are uninfected by EVD; and of course, there is no death. Thus, we set the initial value of the differential equation groups at $S(0) = N, I(0) = 0, D(0) = 0$.

The second task of this model is to determine other essential rules and parameters for our simulation system. Due to **Assumption 1-1**, we set the dispersal rule "four-adjacent" principle respect to the pixels on the map, i.e., if one particular pixel is set as infected status at day n , its four neighbour pixels (upper, lower, left and right one) have probability τ to be affected. Moreover, for the sake of observing the dynamic process of EVD's spread, we trace $t_{max} = 120days$ to generate the simulation results. The evaluation metric is the relative ratio of S, I and D . Another interesting issue is to determine the starting cities of EVD in the simulation. **Assumption 1-1** and the characteristic of Ebola hint us to select those cities with large population and relatively lower hygiene level (although there is no health care interference in this model). Therefore, we survey those potential cities with high EVD risk from WHO annual report[8]: a comprehensive evaluation between population and countries' hygiene level (hospital beds, physician numbers, etc). and eventually select four cities. Our investigation result about those cities is shown in **table 2**.

Table 2: The survey result of four selected cities (data from WHO health statistic 2013)

city	country	city population	hospital beds	physician number
Korhogo	Côte d'Ivoire	174000	1.7	1.4
Kankan	Guinea	193830	1.2	0.9
Bamako	Mali	1800000	0.8	1
Tamale	Ghana	562919	1	2

Remark: hospital beds and physician number are in 10,000 population scale.

2.4 Experiment Result

In this subsection, we exhibit the automatic simulation results of EVD in ideal cases. In **figure 3**, we show the relative S, I, D changing curve with respect to time:

From the simulation figure, we can observe that the susceptible and death curve are changing exponentially. If we choose 80% as the threshold of susceptible, a commonly used index to indicate the harmfulness of one particular pestilence, the milestone happens approximately on the 60th day. The counterpart index of SARS is 64th day[9]. Besides, in the light of the end part of the curve, we can predict that the percentage of death will exceed the percentage of susceptible in the following few days, which means the "collapse" in this area. These facts notifies us that the Ebola is indeed a lethal disease with high infectious rate. In **figure 4**, we visualize the dispersal process by sampling four days simulation results. In **figure 4**, the continent part-




Figure 3: The S,I and D changing curve with respect to time




Figure 4: A dynamic dispersal process of EVD by sampling 1st day, 40th day, 80th day and 120th day

s with original color are uninfected areas(the S area); the pink parts are those districts which have already in collapse condition(the D area); the red outer skirt of the pink parts are districts where are suffering from the EVD(the I area). **Figure 4** inspire us at least in two aspects: 1. the dispersal of Ebola in ideal cases is a diamond-shape infiltration process(this can help us to predict risky districts); 2. As long as several infection districts are connected together, the red outer skirt will dramatically decrease, which means acute increase in death(therefore, we should stop this circumstance from happening).

2.5 Strengths and Weaknesses

- Strengths
 - We successfully model the dispersal process of Ebola with revising the classical **SIR** model into **SID** model and by setting reality parameters to it.
 - By utilizing the simulation system, there is no need to calculate the numerical solution of the differential equation group in **SID** model.
 - The simulation system enables us to visualize the process of dispersal in a direct and human understandable way.
- Weaknesses
 - The primary model fails to evaluate some crucial factors which can affect the spread, for instance, there should be a relationship between the population density and the infection probability τ in a specific region.
 - The simulation process itself may take a considerable time. In fact, we spend over three minutes to fetch the results on a Core-i5 PC with 8GB RAM. Apparently, both of the time and space consumptions are $O(mapSize * t_{max})$.

3 Sub-model 2: SPARD-Improved EVD dynamic dispersal model

3.1 Symbols and Notations

Table 3: Major Symbol and Notation list for sub-model 2

Symbols and Notations	
Symbol/Notation	Definition
$S(x, y, t)$	The number of susceptible people at time t
$P(x, y, t)$	The number of primary infected people at time t
$A(x, y, t)$	The number of advanced infected people at time t
$R(x, y, t)$	The number of recovered people at time t
$D(x, y, t)$	The number of dead people at time t
$N(x, y, t)$	The total population in one district(default: 1 unit)
$\tau(x, y, t)$	The transmission probability from susceptible to primary infected
$\mu(x, y, t)$	The transmission probability from advanced infected to death
$\lambda(x, y, t)$	The transmission probability from primary infected to recovery
$\eta(x, y, t)$	The transmission probability from susceptible to immune
$\phi(x, y, t)$	The transmission probability from primary infected to advanced
t_{max}	Maximum simulation days

3.2 Analysis and Assumptions

In this section, we concentrate our attention on further revising the simple **SID** model mentioned in the former section and improving the accuracy, performance of our own model. Our contributions can be classified into four aspects:

- The residents in one particular district (x, y) at time t is detailed divided into five categories: susceptible, primary infected, advanced infected, recovered and immune, death. All the values of these categories are variables with respect to spatial and temporal.
- We succeed in establishing a numerical relationship between transmission probabilities and the real-time number of five classes above. Thus, the probabilities themselves are also in dynamic status corresponding to time and geography location.
- We succeed in establishing the demand of the medication at (x, y, t) dynamically, and construct an "Early Warning System(EWS)" for vaccine actions.
- In the aspect of delivery system, we take the advantage of graph optimization technique to implement a optimized medication delivering arrangement based on the dynamic actual demands.

The general human classification and their transmission probabilities is shown in **figure 5**. For abbreviation purpose, we name our model as Susceptible, Primary, Advanced, Recovery, Death(SPARD).




Figure 5: The five categories and their relationships of our proposed SPARD dispersal model

Our definition of "Susceptible", "Death" is as same as those in section 2: the primary **SID** model in ideal cases. What needs to be specially explained is: "Primary" status, people who have determined to have infected by EVD but still in primary stage. In other words, this kind of inhabitants are treatable with the aid of our newly invented medication with probability λ . The counterpart of "P" status is "A": advanced infected status. People in this stage are unfortunately incurable by our medicine(because the problem says that the medicine is only valid to early stage people) and they are bounded to death at a constant rate. The transition probability from "P" stage to "A" stage is ϕ . Moreover, thanks to the invention of vaccine by the world medication organization, people in susceptible status are able to become permanent immune to EVD(the "R" status) with probability η .

Besides, in order to further simulate and analysis this model numerically , we put out following model premises. Note that some of them will be explained in detail in next subsections.

- **Assumption 2-1** There is no possibility of natural recovery for any EVD patient, no matter a primary stage one or an advanced stage one.
- **Assumption 2-2** The effect of EVD dispersal at a specific point to its neighbourhood is a circle with constant radius, which modulated by a function.
- **Assumption 2-3** The dispersal abilities of "P" and "A" status patients are different constants.
- **Assumption 2-4** A "P" status patient is usually with slight symptoms and is taken care by five families members(on average) every day. An "A" status patient is looked after by one professional medical staff(on average) during rest lifespan.
- **Assumption 2-5** The medical level and inhabitants' awareness to EVD is a monotonous increase function with respect to time.[10]
- **Assumption 2-6** The average delivery period of both vaccine and remedial drug is a constant.

3.3 Model Description

3.3.1 General Model

We get inspired from our primary sub-model 1 and [11]. With the aid of flow chart shown in **figure 5**, the overall EVD dispersal system in district (x, y) at time t is still described by differential equation group as below:

$$\left\{ \begin{array}{l} S(x, y, t+1) = (1 - \tau - \eta) S(x, y, t) \\ P(x, y, t+1) = (1 - \phi - \lambda) p(x, y, t) + \tau S(x, y, t) \\ A(x, y, t+1) = (1 - \mu) A(x, y, t) + \varphi P(x, y, t) \\ D(x, y, t+1) = D(x, y, t) + \mu A(x, y, t) \\ R(x, y, t+1) = R(x, y, t) + \lambda P(x, y, t) + \eta S(x, y, t) \end{array} \right. \quad (2)$$

The differential equation group above describes the dynamic transition process from time t to time $t + 1$. Nonetheless, as mentioned in last subsection, in **SPARD**, the transition probabilities themselves are also dynamic. In other words, their values depend on the present status of a local point. From 3.3.2 to 3.3.7, we explain our models on these transition probabilities, respectively. In 3.3.8, we will introduce our Early **Warning System(EWS)** in detail. Section 3.3.9 is another graph optimization model concerning transport optimization issue.

3.3.2 Objective Condition Model

According to the guide released intended to helping people fighting against EVD[12], it is highlighted that the hygiene infrastructure level, including hospital beds, laboratories and surveillance ability, along with local inhabitants' awareness to EVD, play crucial roles in eradicating Ebola. In our SPARD model, we generally classify those factors as "Objective Conditions". As far as we are concerned, those objective conditions can be considered as an monotonous increase

function to time, which means that the overall hygiene level and human beings knowledge to EVD is turning better daily(**Assumption 2-5**).

To exemplifier this idea, we collect NGO volunteer number(data from [13, 14, 15]) and Isolation beds(data from [14, 15]) in Liberia as crucial hygienic index provided by WHO from March, 2013 to December, 2014, as shown in **Table 4**. The visualized curve figure is shown in **figure 6**.

Table 4: NGO volunteer number and EVD isolation beds in Liberia

Date	NGO Volunteer Number	Isolated Beds
Mar-13	287	2.3
Jun-13	296	2.6
Sep-13	311	3.1
Dec-13	363	3.4
Mar-14	533	3.41
Jun-14	611	3.7
Sep-14	642	4
Dec-14	684	4.2

Remark 1: NGO volunteer number is collected on: <http://www.arda.org>

Remark 2: Isolated beds number is in 10,000 population scale. collected from: <http://www.emergency.it>




Figure 6: The visualized changing curve of NGO volunteer number and isolated beds number from Mar, 2013 to Dec, 2014

From **figure 6**, we can find that both the volunteer number and the number of isolation ward have always been increasing since March, 2013. In our opinion, the objective conditions level can be described with a logistic function[16] in order to reflect the process of relieving the effect of EVD dispersal resulted form objective conditions. Compared with **figure 6**, it is also reasonable to do so from the angle of functional fitting. Therefore, we define "Objective Condition Index" as below:

$$OCI(x, y, t) = \frac{1}{1 + e^{-\frac{t}{30}}} \quad (3)$$

What is amazing is that the shape of logistic function fits the blue curve(NGO volunteer

number) quite well! This function implies that the *OCI* can be viewed as a "discount"(range from 0-1) over the transition probability between a slight case to a severe one(S-P, P-A, etc).

3.3.3 S-P Transition Model

As far as we are concerned, the susceptible-primary stage transition probability is the core attribute to describe the EVD dispersal dynamic process, because it requires us to consider lots of inherent status of the location, i.e., the ratio among S, P, A, R, D people. First, we define the potential average number of an Ebola patient(both P and A types) can spread his or her virus, as the District Dispersal Index: *DDI*:

$$DDI = \frac{S}{S+R} (P \times 5 \times 23\% + A \times 1 \times 81\%) \times OCI(x, y, t + 1) \quad (4)$$

$\frac{S}{S+R}$ is the ratio in healthy locals who can be infected by Ebola("S" people are not immune yet, whereas "R" ones are immune). Due to **Assumption 2-3**, we investigate the fact[17] that, a "P" status patient has 23% probability to spread disease to others; the same value of a "A" status one is 81%. Moreover, according to **Assumption 2-4**, we add five(average families members number per "P" patient) and one(average medical staff number per "A" patient) to the inner product terms, respectively. Generally speaking, the *DDI* tells us how many susceptible people can be infected in a particular district without considering inter-district spread cases under present situation. Finally, we add the *OCI* term, to simulate the effect of objective conditions.

In order to calculate the precise ratio of S-P transition probability, i.e., the $\tau(x, y, t + 1)$, we need to take district (x, y) neighbourhood into consideration. There is a fact that a relatively farther district (x_1, y_1) has less dispersal impact on (x, y) than a near one (x_2, y_2) . We utilize a two dimension Gaussian function $Gau(x, y)$ to conduct a convolution integral with $DDI(x, y, t)$ on spatial scale:

$$\begin{cases} Gau(x, y) = \exp\left(-\left(\frac{x^2 + y^2}{\sigma^2}\right)\right) \\ \tau(x, y, t + 1) = \mathbf{conv}[DDI(x, y, t), Gau(x, y)] \end{cases} \quad (5)$$

Note that in $Gau(x, y)$, the deviation coefficient σ , is a parameter to control the degree of popular density at neighbourhood around district (x, y) : imaging that for those metropolitan, σ should be relatively large, because they have much stronger EVD radiation ability. **Figure 7** shows our settings of $Gau(x, y)$ for metropolitan($\sigma = 250$), and normal villages($\sigma = 150$), respectively.

3.3.4 A-D Transition Model

Unfortunately, the A-D transition ratio describes the process of advanced stage Ebola patient coming to death. In the light of an epidemic disease report [16] and our own investigation of the severe symptoms of advanced stage EVD patients(including fever, rash, vomiting, bleeding, etc), we give **Assumption 2-1** which means that the advanced EVD patients have no possibilities to recover and die at a fixed rate every day. We set this ratio at 20%. Thus, we have $\mu = 0.2$.




Figure 7: The two dimension Gaussian function utilized to **conv** with DDI

3.3.5 P-A Transition Model

Thanks to the improvement in objective condition: the increase of *OCI* with respect to time, we consider the transition probability from primary EVD to advanced EVD $\phi(x, y, t)$ a constant multiplied by the updated *OCI*:

$$\phi(x, y, t + 1) = \phi(x, y, t) \times OCI(x, y, t + 1) \quad (6)$$

3.3.6 P-R Transition Model

The P-R transition probability λ means the ratio of inhabitants, who have caught Ebola with slight symptoms, be cured on a particular day. According to our common sense, this index is an monotonous increase function with respect to time: the quality and performance of our newly invented medicine needs a process to be improved and become stable at last. This idea can be viewed as a simple deformation of **Assumption 2-5**. However, there is not any EVD-specific remedial medicine manufacturing data available yet. Thus, in order to attest our assumption, we cite the Yield-Time curve of the first counterpart for SARS, manufactured since Dec, 2004[18]. Then we conduct a regression analysis to achieve our λ as shown in **figure 8**.

We employee a logarithm function to regress the result. Therefore, our λ is defined as:

$$\lambda(x, y, t + 1) = 0.195 \ln \left(\frac{t}{30} \right) + 0.35 \quad (7)$$

3.3.7 S-R Transition Model

The S-R transition probability $\eta(x, y, t)$ directly reflects the performance of vaccine medication. Apparently, for model simplification purpose, we utilize the **Assumption 2-5** like the P-R transition model again. However, the salient difference between P-R model and S-R model is that the speed of manufacturing a brand-new vaccine is much slower than that of remedial medicine. In this degree, the performance of the vaccine is determined as below by degrading




Figure 8: The Yield-Time curve of remedial medicine for SARS, the regression result is used to describe our λ (Note that the temporal scale is month)

the coefficients in some degree.

$$\eta(x, y, t + 1) = 0.080 \ln \left(\frac{t}{30} \right) + 0.1 \quad (8)$$

3.3.8 Medication Demand and EWS

Just as mentioned in previous sections, in our **SPARD** dispersal model, the medication is divided into two classes: vaccine and remedial drug. The **EWS** is meant to dynamically telling people the reasonable medication amount according to the evaluation results and real-time attributes in a specific area.

In the aspect of remedial drug demand, the situation is relatively easy to understand. The core principal is "How many sick, how much drug". Combining with **Assumption 2-1**, we only need to concentrate our attention on treating the "P" state patients and the **potential patients** before the next drug delivery period T (**Assumption 2-6**). Because the transition probability at time t is τ , and we have susceptible inhabitants $S(x, y, t)$, primary symptom people $P(x, y, t)$. We arrange the remedial drug amount by predicting there will be τ ratio people caught EVD in the next T days. Thus, the demand for remedial drug $DEM_r(x, y, t)$ is given as below:

$$DEM_r(x, y, t) = S(x, y, t) \sum_{i=0}^T (1 - \tau)^i \tau \quad (9)$$

On the other hand, the vaccine plays an important role in controlling the trend of EVD dispersal by lowering the risk of inhabitants in a specific region to get caught the Ebola, i.e., lowering the value of τ and increase the value of η . Nevertheless, as we have deduced in S-P transition model, the probability of catching a EVD is not only determined by the intra-district factors, but the neighbourhood regions, as well. On the basis of this premise, we use the *DDI* attribute and the "convolution integral" trick in S-P Transition Model again to calculate the demand for

vaccine $DEM_v(x, y, t)$:

$$DEM_v(x, y, t) = \mathbf{conv}[DDI(x, y, t), F_{vacc}(x, y)] \quad (10)$$

However, in this case, we abandon the classical two dimension Gaussian function to conduct the convolution. Instead, we define $F_{vacc}(x, y)$ in polar coordinate as $F_{vacc}(\rho, \theta)$ as following:

$$F_{vacc}(\rho, \theta) = \begin{cases} \log e \left(\frac{1}{4} \rho \right), & 0 < \rho < 7 \\ 2.6 \left(\frac{e}{2} \right)^{9-\rho}, & \rho \geq 7 \end{cases} \quad (11)$$

The corresponding figure of $F_{vacc}(x, y)$ is shown in **figure 9**.




Figure 9: The 3D curve of our $F_{vacc}(x, y)$

Now, let us analysis the physical meaning and connection to **EWS** of this "weird" function. Given a specific severe infected region (x, y) , our goal is to prevent the process of EVD spread by arranging reasonable vaccine medication. We manually divide the neighbourhood of (x, y) into two classes.

The first classes includes those areas within a circle with radius at 7 unit length. Apparently, these areas are the most "dangerous" places, the absolute number of "P" status will sharply increase in a few days. Unfortunately, as you known, there always exists a "postpone" effect on the vaccine. In other words, it is too late to prevent EVD outbreak in these areas by distributing vaccine in short term. Actually, this action may even cause "excessive gathering" and panic among locals, as [19] mentioned. This phenomenon explains why we set the nearest part(radius less than 7) around $(0, 0)$ as negative. As to the second class parts, those areas with radius larger than the threshold 7, the vaccine should be monotonously decrease respect to distance, with the same purpose by employing Gaussian function in 3.3.4. This is just a crucial strategy in our **EWS**: "DO NOT waste vaccine resource on those most risky areas".

Overall, our **EWS** model designed for early warning and dynamic medication arrangement innovatively provides professions with direct and accurate real-time EVD dispersal evaluation metric. In addition, the authority can utilize **EWS** as an aid tool, to design daily transport plan.

3.3.9 Transport Optimization

In this section, we are meant to work out an optimized transport plan for the vaccine and remedial medicine. Because the expense of building a new airport will be considerable, our first mission is to minimize the total number of airports in the whole district. In order to simplify the task, we decompose the whole restrict into several hexagon subregions. Besides, we suppose that there is a small-scale size airport built for EVD in the middle of each hexagon. The idea to do so is inspired from the "cellular network" in Communication Engineering fields. Actually, this conclusion comes from **Theorem 3.1**.

Theorem 3.1. *If we want to cover a plane with circles in same radius, when the circle center is the same as the gravity center of each hexagon in the hexagon grids, the total number of the circle is minimized.*

According to **Theorem 3.1**, we construct a cellular airport network as below:




Figure 10: The airport construction plan in western coast of Africa

In this way, we are able to cover the whole epidemic region with minimized airport number. The second task in our transport optimization model is to select several optimized airports as basements. In this task, we take the EVD dispersal situation every day into consideration. As mentioned in section 3.3.8, we have already defined the exact demand for remedial drug and vaccine as $DEM_\tau(x, y, t)$ and $DEM_v(x, y, t)$, respectively. Therefore, we can furthermore define a weight at each airport representing the "emergency degree for medication" for each hexagon region R_i :

$$w_i = \iint_{R_i} (DEM_\tau(x, y) + DEM_v(x, y)) dR_i \quad (12)$$

Then the task can be furthermore transfer into a graph optimization problem. Suppose we have n airports with coordinates (x_j, y_j) , $j = 1, 2, \dots, n$, with weights w_j , $j = 1, 2, 3, \dots, n$. Our mission is to find k (the value depends on the general transport ability) basements (x_i, y_i) , $i = 1, 2, \dots, k$ to minimize the following object function L , where d_{ij} is the l2-norm between (x_i, y_i) and (x_j, y_j) :

$$L = \sum_{i,j} w_j d_{ij} \quad (13)$$

Algorithm 1 Finding the best k basements by K-median point

Input: $w_j, (x_j, y_j), j = 1, 2, \dots, n$

Output: $(x_{qi}, y_{qi}), i = 1, 2, \dots, k$ and c_{ij}
do

1. Randomly select k points as (x_{qi}, y_{qi}) .
2. Group airports (x_j, y_j) to the k points by "minimize-distance" principle, i.e.:
 $c_{ij} = 1$, where $d_{ij} = \min_k d_{kj}$. c_{ij} is the adjacent matrix of the optimized graph.
3. Calculate the weighted geometry center in each airport group: (x'_{qi}, y'_{qi}) .
4. Calculate L_i and L'_i respectively, let $\varepsilon = \sum_{i=1}^k L_i - L'_i$.

while ε not converge

we solve this problem by the following **K-median point** algorithm in graph optimization theory as mentioned in [20]:

Thanks to the weight is calculated directly from the demand of medication, this optimized transport plan is coherently connected with our **EWS**. Thus, it can provide authority with a meaningful delivery suggestion.

3.4 Experiment Result

In the experiment section, we conduct the simulation experiment in two aspects. In the first part, in order to exhibit the transport optimization result, we sample one of the daily simulation result of the EVD dispersal and show our optimized plan in illustration form. In the second experiment, we verify the effect of our **SPARD** model and corresponding strategies by thoroughly comparing the simulation result under human interference condition with that without any medication supply(i.e., the ideal dispersal model).

First, let us verify our transport optimization model. We sample the 50th days' dispersal figure to deduce medication demand amount in one round of **SPARD** simulation under human interference conditions. **figure 11** is a coloured dynamic picture. The green regions are those areas which have majorly immune to EVD thanks to our **EWS** system. It is clear that in **figure 11**, there also includes a purple coloured stripe: the heated district where is suffering from EVD. Although there is another dark black sector(districts with people are almost all in "A" status), according to our principle in **EWS** model, the stripe area should be the on the top of our medication delivery list.

With the real-time value of $DEM_\tau(x, y)$ and $DEM_v(x, y)$ generated from our system, we then calculate the weight w_i for each hexagon region center(the values are shown in **figure 12** with red color). The real-time values of w_i also reflect our guess in **EWS** in another way.

By conducting our **K-median point** algorithm, we eventually get the optimized transport plan under $k = 3$. We label the airport selection plan with three different coloured lines in **figure 12**. In addition, we work out the homologous minimized object function value $L_{min} = 1059$.




Figure 11: The raw EVD dispersal figure on day 50



Figure 12: The corresponding optimized air basement arrangement of figure 11

Now it is time for us to overall evaluate the actual effect of **SPARD** with the classical **SID** model. Once again, we exhibit the evaluation result by vivid illustrations shown in **figure 13**.

In the left part of **figure 13**, we show the simulation results of EVD spread in ideal **SID** model on sampled days(10th day, 60th day, 90th day and 150th day). On the contrary, the right part shows the result of optimized **SPARD** model. In general, we represent the continent with cyan and the ocean with pure blue. Note that the dark purple part on the continent represents districts with residents majorly in "D" status, i.e, the terrify "collapse" caused by Ebola. Moreover, the green part is our vaccine covered area, with majorly R status people. Comparing with the simulation result of **SID**, our improved **SPARD** model have the following apparent advantages:

- The simulation process itself is much more realistic. Both the left and right spread processes are no longer regular circles with gradually increasing radius.
- Comparing the left figures with right ones, our core strategies in **SPARD** have salient performance on impeding Ebola death rate: the spaces of purple regions are all much smaller than the left ones.
- The **EWS** mechanism also predicts the trend of EVD spread accurately: those green areas are exactly the spread directions in left figures.

In order to numerically compare the performance between **SPARD** with **SIR**, we plot the absolute number changing curves for S, P, A type residents in **figure 14**. The object region is the whole Western Africa continent. The strategies mentioned above give us with perfect performances in all three data curves: the susceptible cases number decrease much slower than that in **SID** settings, particularly after 100 days; the primary cases number in our model is kept stable throughout the whole simulation iterations; as to the advanced EVD patients number, thanks to the invention of the medication and our **EWS** action, the result is amazingly outstanding. Overall, the Azrael, Ebola is suspended by human beings after 200 days! Besides, the raw data in the iteration process is provided in Appendix.

3.5 Strengths and Weaknesses

- Strengths
 - In our **SPARD** model, all parameters are dynamic changing with respect to the process of human being's fighting against Ebola. Thus, we endow all the parameters in the model with touchable physical meanings.
 - We innovatively propose an early warning mechanism to impede the spread of Ebola. Governments and organizations can use the **EWS** to constitute scientific decisions.
 - The **SPARD** model also provides a reasonable solution to the tricky medication delivery problem with the inspiration from modern communication systems.
- Weaknesses
 - Because of the time issue in this competition, some of the parameters in our model are lack of strict sensitivity analysis. Thus, some models may need further modification and tuning.
 - The simulation process itself takes a much longer time than sub-model 1 due to the great expansion in variables. We are even obliged to make use of a updated workstation to run our simulation program.




Figure 13: The dynamic dispersal illustrations under SPARD framework with and without medication supply, respectively.




Figure 14: The S, P, A dynamic changing curve in SPARD with respect to time

4 Conclusion

In this paper, we establish two models to solve the problem concerning with eradicating the Azrael, Ebola. In model 1, we simply change the ordinary **SIR** model into **SID** by making some basic assumptions specific for observing Ebola's dispersal in ideal environments. The simulation result shows us an impressive spread ability of the lethal virus. Our attention is majorly concentrated on the second sub-model: **SPARD**. In this model, we design a dynamic process of the transition probabilities among those people classes. Therefore, the simulation result is much more precise and reasonable compared with the former one. Besides, the **SPARD** model also provides professions, governments and NGOs with an automatic early warning system, along with a complete solution plan to help fighting against EVD. Considering the fact that this MCM problem is not only challenging but also with practical senses, our team have decided to furthermore exploit the performance of our model. We plan to improve our model by using our knowledge in Machine Learning and Data Mining fields. For example, the simulation speed can be greatly improved by CUDA, a parallel calculation technology provided by NVIDIA [21]. The up-to-date codes and models can be viewed at our Github page(E-mail us if needed).

5 The non-technical letter

Dear world citizens,

We are pleased to announce our recent breakthrough in eradicating Ebola virus fields. After several years continuous dedicated work, our top-level research team has successfully manufactured the vaccine along with the medication which can impede the step of Ebola.

As you known, at present, the lethal virus is raging on the western coast of the African continent. Every day, hundreds of our compatriots are suffering from the pain caused by Ebola. In fact, human beings are going through the toughest times to fight against the disease.

Therefore, for the humanitarian reasons, we have decided to provide our newly invented medicine and vaccine for free to those inhabitants in high risk districts. According to a recent proposed paper concerning fighting against Ebola, the manufacturing speed of our medicine plays an crucial role in impeding its step. Thus, we are contacting closely with the best drug manufacturers at present in order to realize a stable and high quality production as soon as possible. Please trust us, there is no need to worry too much about the deadly disease.

Moreover, we have to remind you that every individual is an essential part on the frontline eradicating Ebola. As a worldwide health organization, we hope you to embrace the following personal habits to help us avoiding Ebola:

- Washing your hands and taking shower regularly as long as it permits;
- Avoiding visiting the epidemic area except you have professional protective equipments;
- Paying attention to the food you purchase, refuse those potential ingredients coming from the epidemic districts;
- Never hesitating to report to the local hygiene departments if you find yourself or friends have suspicious symptoms: fever, vomiting, rash, abnormal bleeding, etc;
- Keeping yourself updated with the dispersal news and prepare yourself if needed.

With the corporation from all the human kinds, we believe that the Ebola will ultimately be eliminated in the near future. God bless you! God bless Africa!

Yours sincerely,

The World Medication Organization

References

- [1] World Health Organization. Fact sheet of ebola virus disease. <http://www.who.int/mediacentre/factsheets/fs103/en/>.
- [2] World Health Organization. Guidance for immunization programmes in the african region in the context of ebola. http://apps.who.int/iris/bitstream/10665/137330/1/WHO_IVB_14.08_eng.pdf?ua=1.
- [3] WHO Ebola Response Team. Ebola virus disease in west africa—the first 9 months of the epidemic and forward projections. *N Engl J Med*, 371(16):1481–95, 2014.
- [4] World Health Organization et al. Ebola and marburg virus disease epidemics: preparedness, alert, control, and evaluation. 2014.
- [5] Rouven J Wool-Lewis and Paul Bates. Characterization of ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. *Journal of virology*, 72(4):3155–3160, 1998.
- [6] C Connell McCluskey. Complete global stability for an sir epidemic model with delay—distributed or discrete. *Nonlinear Analysis: Real World Applications*, 11(1):55–59, 2010.
- [7] Stanislas Rebaudet, Sandra Moore, and Renaud Piarroux. Ebola virus disease in west africa—the first 9 months. *The New England journal of medicine*, 372(2):188–188, 2015.
- [8] World Health Orgnization. World health statistics 2013-[buku].
- [9] Michael Small, CK Tse, and David M Walker. Super-spreaders and the rate of transmission of the sars virus. *Physica D: Nonlinear Phenomena*, 215(2):146–158, 2006.
- [10] World Health Organization (WHO) et al. Who: Ebola response roadmap situation report. 1 october 2014. geneva: Who.[accessed 8 oct 2014].
- [11] Boris Shulgin, Lewi Stone, and Zvia Agur. Pulse vaccination strategy in the sir epidemic model. *Bulletin of Mathematical Biology*, 60(6):1123–1148, 1998.
- [12] Jeremy Gradon. An outbreak of ebola virus: Lessons for everyday activities in the intensive care unit. *Critical care medicine*, 28(1):284–285, 2000.
- [13] Tolbert Nyenswah, Miatta Fahnbulleh, Moses Massaquoi, Thomas Nagbe, Luke Bawo, James Dorbor Falla, Henry Kohar, Alex Gasasira, Pierre Nabeth, Sheldon Yett, et al. Ebola epidemia—liberia, march–october 2014. *MMWR Morb Mortal Wkly Rep*, 63:1082–6, 2014.
- [14] Adventist Development and Relief Agency. Arda’s response towards ebola in liberia. <http://www.adra.org/>.
- [15] The Emergency. Emergenza ebola, abbiamo bisogno del tuo aiuto. <http://www.adra.org/>.
- [16] Scott F Dowell, Rose Mukunu, Thomas G Ksiazek, Ali S Khan, Pierre E Rollin, and CJ Peters. Transmission of ebola hemorrhagic fever: a study of risk factors in family members, kikwit, democratic republic of the congo, 1995. *Journal of Infectious Diseases*, 179(Supplement 1):S87–S91, 1999.
- [17] Shengxue Mu. Ten ground truch must be recovered about ebola. http://blog.sina.com.cn/s/blog_544838700102vfml.html.

- [18] Lisa E Hensley, Elizabeth A Fritz, Peter B Jahrling, Christopher Karp, John W Huggins, and Thomas W Geisbert. Interferon- β 1a and sars coronavirus replication. *Emerging infectious diseases*, 10(2):317, 2004.
- [19] Sheldon Ungar. Hot crises and media reassurance: A comparison of emerging diseases and ebola zaire. *British Journal of Sociology*, pages 36–56, 1998.
- [20] Sarel Har-Peled and Akash Kushal. Smaller coresets for k-median and k-means clustering. In *Proceedings of the twenty-first annual symposium on Computational geometry*, pages 126–134. ACM, 2005.
- [21] NVIDIA Corporation. The cuda zone. http://www.nvidia.com/object/cuda_home_new.html.

Appendices

Appendix A Raw data in SPARD model

A.1 Western African city data used in our simulation

Table 5: Western African city data

city name	x	y	population(1000)	city size
Daker	41	40	500	large
Banjul	51	72	500	large
Bissau	73	114	500	large
Conakry	151	183	500	large
Freetown	148	212	500	large
Monrovia	205	262	500	large
Bamako	280	96	500	large
Yamoussoukro	350	248	500	large
Ouagadougou	449	100	500	large
Accra	489	283	500	large
Saint-Louis	53	15	375	medium
Diourbel	60	38	375	medium
Kaolack	50	52	375	medium
Serrekunda	49	85	375	medium
Ziguinchor	59	100	375	medium
Kayes	188	42	375	medium
Kindia	153	168	375	medium
Kankan	246	165	375	medium
Koidu	199	212	375	medium
Kenema	192	232	375	medium
Man	283	242	375	medium
Korhogo	343	176	375	medium
Koutiala	346	113	375	medium
Mopti	377	42	375	medium
Segou	325	72	375	medium
Daloa	322	250	375	medium
Gagnoa	351	263	375	medium
Abengourou	395	246	375	medium
Abidjan	384	292	375	medium
San-Pedro	314	306	375	medium
*DO NOT include random cities				

A.2 Simulation raw data of S, P, A(sampled with 5 days interval)

Table 6: Simulation raw data of S, P, A(sampled with 5 days interval)

day	S(with med)	S(without med)	P(with med)	P(without med)	A(with med)	A(without med)
5	14976623	14976369	252350	250705	108349	111075

10	14738090	14737688	242830	244329	194750	204560
15	14530769	14528287	215514	227892	201437	223864
20	14329028	14321353	195705	222019	183487	223662
25	14111004	14094203	185644	232828	169016	229464
30	13877055	13853705	176708	241358	159261	242268
35	13677715	13644777	134508	224921	133028	236912
40	13475748	13424671	105564	228296	101835	231394
45	13281873	13196534	84683	236752	77191	232168
50	13056665	12910363	91887	278823	64340	252104
55	12805749	12642965	108335	275748	64595	273871
60	12577016	12361087	102214	289777	60879	280214
65	12343194	12020161	101806	335642	51948	302659
70	12065897	11627542	129357	385074	52964	343366
75	11745289	11226831	178484	401485	72344	383971
80	11407989	10868984	227860	380513	99005	391497
85	11102780	10492122	235726	389367	113982	388249
90	10811852	10106981	221931	396813	112636	394796
95	10524957	9708419	211823	410794	106661	402641
100	10244242	9253499	208487	454814	99440	425921
105	9964654	8756677	204480	493391	95011	465931
110	9674931	8310848	207194	470739	95709	481452
115	9356791	7856101	231756	473636	98878	478255
120	9028581	7409922	263886	465844	102242	478702
125	8712221	6980690	280787	455296	104754	468732
130	8409114	6516381	281887	475411	107876	471968
135	8114938	6046523	274147	485033	107626	483124
140	7811628	5563885	271326	497476	106817	493312
145	7511821	5062757	269756	514337	108683	507369
150	7229198	4547124	252508	528814	107947	523439
155	6952562	4038297	231148	530155	103293	532049
160	6666080	3502737	217556	547673	99588	544252
165	6353021	3022293	228397	512139	95908	544043
170	6029395	2575120	249268	480538	95248	518447
175	5699390	2161231	270662	443396	98162	490278
180	5370738	1811827	288558	385364	100922	448661
185	5039376	1520986	309303	328427	106540	392406
190	4705252	1245123	323539	299157	116403	345440
195	4357208	1027669	343005	246405	128272	303391
200	4005844	854749	360557	201464	141712	253183
205	3650781	697349	377906	174591	151196	214176
210	3300298	562707	386778	151656	157306	181739
215	2977117	433580	368580	138406	161137	160864
220	2688953	334988	321209	112979	155327	140427
225	2424911	256396	270078	91397	142230	116611
230	2181498	193151	216114	73996	127091	95368